Zydus Lifesciences Acquires 85.6% of Amplitude Surgical and Launches Mandatory Tender Offer

PAI Partners Agrees to Acquire Majority Stake in Amplitude Surgical

July 30, 2020

Medical Devices

PAI Partners has entered into exclusive negotiations to acquire a majority stake in Amplitude Surgical from Apax Partners and certain managers via an SPV, at a price of €2.15 per share, with a subsequent mandatory public tender offer planned. The transaction preserves existing management involvement and is intended to support Amplitude Surgical's continued international expansion and product development in lower-limb orthopedics.

Novartis to Acquire MorphoSys in $2.9 Billion Deal

February 7, 2024

Pharmaceuticals

Novartis agreed to a voluntary public takeover offer to acquire MorphoSys AG for €68 per share, valuing the deal at about €2.7 billion (reported as $2.9 billion). The acquisition is intended to expand and complement Novartis’ oncology pipeline, including pelabresib (CPI-0610) and tulmimetostat (CPI-0209).

Surgical Notes Acquires Zulu Health

August 6, 2021

Healthcare Services

Surgical Notes has acquired Zulu Health, a Los Angeles-based revenue cycle management (RCM) provider focused on ambulatory surgery centers (ASCs). The deal brings Zulu Health's leadership and RCM capabilities into Surgical Notes (a CapStreet Group portfolio company) to expand and strengthen ASC-focused RCM services nationwide.

Zimmer Biomet Acquires A&E Medical Corporation

December 1, 2020

Medical Devices

Zimmer Biomet completed the acquisition of A&E Medical Corporation from private equity owner Vance Street Capital for $250 million. A&E Medical, headquartered in Farmingdale, New Jersey, is a designer and manufacturer of sternal closure systems, cardiac pacing wires and related disposable surgical products; the deal expands Zimmer Biomet's capabilities and product portfolio in cardiovascular and cardiothoracic surgical devices.

Genmab A/S Acquires Merus N.V. via Tender Offer

December 12, 2025

Biotechnology

Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.

Zydus Lifesciences Acquires Agenus' U.S. Biologics Manufacturing Facilities and Launches Zylidac Bio LLC

January 16, 2026

Biotechnology

Zydus Lifesciences Limited has completed purchase agreements with Agenus Inc. to acquire Agenus' biologics manufacturing facilities and operations in Emeryville and Berkeley, California, and has established a U.S. CDMO subsidiary, Zylidac Bio LLC, to operate the assets. The deal includes exclusive manufacturing arrangements for Agenus' Phase 3 immuno-oncology candidates (botensilimab and balstilimab), exclusive commercialization rights for those assets in India and Sri Lanka, and an equity investment in Agenus via Zynext Ventures; regulatory approvals including CFIUS clearance were secured.